Please assess the completion status of the following clinical trial:

Trial Title: Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. 19 and under 80 years~2. Histologically confirmed prostate adenocarcinoma~3. Patients with stage M1a or M1b with extrapelvic lymph nodes and bone metastases~4. Patients diagnosed with castration-resistant prostate cancer after failure of male hormone deprivation therapy (Castrate levels of testosterone \<50 ng/dL) and If either a or b is satisfied:~   1. Biochemical progression: Prostate Specific Antigen (PSA) increases three times in a row at 1 week intervals, two 50% increases compared to the lowest point, PSA\> 2ng/mL, or~  2. Radiological progression: appearance of new lesions; 2 or more new lesions on the bone scan~5. Asymptomatic or mild patients after previous treatment~   1. Patients who have not used narcotic analgesics within 21 days prior to enrollment~  2. Patients with an average weekly pain of less than 4 on the Visual Analogue Scale(VAS) (out of 10)~6. Combination of Luteinizing hormone-releasing hormone(LHRH) analogs (leuprolide (Lupron, Viadur, Eligard) and goserelin (Zoladex, etc.) for the inhibition of gonadotropin is allowed~7. Whole body performance status: European Cooperative Oncology Group(ECOG) 0\~1~8. Patients whose life expectancy is at least 6 months or longer~9. Hb ≥ 8.0g/dL, Absolute Neutrophil Count(ANC) ≥ 1,500/mm3, Platelets ≥ 100,000/mm3~10. Serum Creatinine ≤ 2.0 x Upper Limit of Normal(ULN) or Calculated Creatinine Clearance \> 30mL/min~11. Total Bilirubin ≤ 1.5 x ULN or Direct bilirubin ≤ ULN, Aminotransferase (AST)/Alanine aminotransferase(ALT) \<2.5 x ULN~12. Patients who did not receive surgery, radiation therapy, or immunotherapy within the last 6 weeks and recovered from side effects~13. Patients who agreed to use medically recognized contraceptive methods during the clinical trial participation period~14. Patients who voluntarily participated in clinical trials and signed the Informed Contents Form (ICF)~Exclusion Criteria:~1. Patients who have a local recurrence and are scheduled for local treatment.~2. Patients with malignant tumors other than non-melanoma skin cancer in the past 3 years~3. Patients with visceral metastases (metastases to the lungs, liver, adrenal glands, peritoneum, brain, etc.)~4. Patients who previously received anti-tumor immunotherapy (anti-PD1, anti-PDL1 or anti-PDL2, etc.) or participated in immunotherapy-related clinical trials~5. Patients with active autoimmune diseases requiring systemic immunosuppression treatment (e.g., immunosuppressants such as cyclosporin A or azathioprine or steroids for disease control)~6. Patients with medical conditions requiring continuous or intermittent administration of systemic steroids or immunosuppressants~7. Patients who received blood products (limited to whole blood products) within 4 weeks of screening criteria, or patients who received colony stimulating factors (Colony Stimulating Factor or recombinant Erythropoietin)~8. Patients with a history of organ or hematopoietic stem cell transplantation~9. Patients with acute or chronic infections requiring systemic treatment~10. Patients known to be infected with human immunodeficiency virus (HIV)/serum positive~11. Patients with active hepatitis A, B or C~12. Patients with untreated syphilis (Fluorescent Treponemal Antibody Absorption Test (FTA-ABS) Immunoglobulin M positive patients)~13. Patients expected to require therapeutic biotherapy or immunotherapy~14. Patients who received live virus vaccines (e.g. measles, mumps, rubella, chickenpox, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), oral typhoid vaccine, Flu-Mist, etc.) within 30 days~15. Patients with a history of anaphylaxis to gentamicin~16. Others, if the person in charge of the study determines that it is not suitable for the clinical trial

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Cellgram-DC-PC (Type: EXPERIMENTAL): Cellgram-DC-PC is injected subcutaneously near the inguinal lymph nodes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues